ReviewAnnals of translational medicine2023
A new era of gene and cell therapy for cancer: a narrative review.
Review in Annals of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Interventional effects of mesenchymal stem cells on epithelial-mesenchymal transition in head and neck squamous cell carcinoma and underlying mechanisms: a systematic review and meta-analysis ofFrontiers in immunology · 2025Pooled it
- Performance of a modular robotic cluster matches skilled human operators for complex cell therapy manufacturing tasks.International journal of pharmaceutics: X · 2026Article
- Landscape ofMolecular therapy. Methods & clinical development · 2025Article
- Cutting-edge treatments in amyotrophic lateral sclerosis: the role of molecular pathogenesis in targeted therapies.Stem cell research & therapy · 2025Review
- Mediating Role of the ANGPTL3/TFPI Protein Ratio in Regulating T-Cell Surface Glycoprotein CD5 Levels on Knee Osteoarthritis (KOA): A Mendelian Randomization Study.International journal of molecular sciences · 2025Article
- Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups.Current issues in molecular biology · 2025Review
- Unlocking the potential of tumor-targeting peptides in precision oncology.Oncology research · 2025Review
- Cytotoxic Potential of Novel Quinoline Derivative: 11-(1,4-Bisaminopropylpiperazinyl)5-methyl-5H-indolo[2,3-b]quinoline against Different Cancer Cell Lines via Activation and Deactivation of the Expression of Some Proteins.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: With the development of cytology and genomics, genetically modified immune cells have established their role from principle to clinical applications, achieving outstanding therapeutic effects in hematologic malignancies. However, even though encouraging initial response rates, many patients experience a relapse. In addition, there are still many obstacles preventing the use of genetically modified immune cells in treating solid tumors. Nevertheless, the therapeutic effect of genetically engineered mesenchymal stem cells (EMSCs) in malignant diseases, especially solid tumors, has been widely investigated, and related clinical trials are gradually being carried out. This review aims to describe the progress of gene and cell therapy and the current status of stem cell clinical trials in China. This review focuses on the research and application prospects of genetically engineered cell therapy using chimeric antigen receptor (CAR) T cells and mesenchymal stem cells (MSCs) for cancer. Methods: A literature search of PubMed, SpringerLink, Wiley, Web of Science, and Wanfang database was carried out for published articles on gene and cell therapy up to August 2022. Key Content and Findings: This article reviews the development of gene and cell therapy and the current status of the development of stem cell drugs in China, with a particular focus given to the advent of the novel therapy of EMSCs. Conclusions: Gene and cell therapies have a promising therapeutic effect on many diseases, especially recurrent and refractory cancers. Further development of gene and cell therapy is expected to promote precision medicine and individualized therapy and open a new era of therapy for human diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.